NEUROLOGIE WETENSCHAPPELIJKE ARTIKELS AUTEURS: Chaudhuri K, Kovacs N, Pontieri F, Aldred J, Bourgeois P, Davis T et al. JOURNAL: Neurology TITEL: Long-Term Motor and Non-Motor Symptom Benefits in Patients With Advanced Parkinson's Disease treated With Levodopa-Carbidopa Intestinal Gel: Final analysis of the 36-Month DUOGLOBE Real-world Multinational Observational Study (P1-1.Virtual) VOLUME: 98 ISSUE: s18 PAGINA’S: 1457 JAAR: 2022 DOI: Online ISSN: 1526-632X ABSTRACT: RESULTS: Of 188 patients with baseline H&Y scores, baseline characteristics in both groups were similar except mean (SD) UPDRS II (<3, 10.7 [6.7]; ≥3, 16.8 [7.6]) and III (<3, 19.3 [9.4]; ≥3, 31.7 [13.0]). Strong, significant improvements were observed in “Off” time through M36 in both groups (<3, P<.01; ≥3, P<.001). In <3, UDysRS total scores improved significantly until M12 (P<.05) and numerically through M36, and significantly improved through M36 (P<.05) in ≥3. Sustained improvements in NMSS were observed in both groups (both P<.05), with significant improvements in PDQ-8 until M18 (<3, P<.05; ≥3, P<.01). Both groups showed a significant increase in UPDRS II and III scores at M36 (UPDRS II <3, P<.001; ≥3, P<.05; UPDRS III <3, P<.01; ≥3, P<.05). Axial symptoms worsened in <3 (P<.001) but remained generally stable over time in ≥3. SAEs and discontinuation rates were generally similar in both groups. Conclusions: This first reported long-term analysis in patients who received LCIG in different H&Y stages suggests patients experience important benefits from LCIG treatment independent of H&Y stage. Safety was consistent with the established LCIG safety profile. AUTEURS: Kovács N,Bergmann L, Anca-Herschkovitsch M, Cubo E, Davis TL, Iansek R, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR, Bourgeois P, Gao T, Kukreja P, Pontieri FE, Aldred J Journal: Journal of Parkinson's Disease today TITEL: Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel VOLUME: 12 ISSUE: 3 PAGINA’S: 917-926. JAAR: 2022 DOI: doi: 10.3233/JPD-212979. ABSTRACT: BACKGROUND: It is believed that motor symptoms, including dyskinesia, and non-motor symptoms impact health-related quality of life (HRQoL) in patients with Parkinson's disease (PD), and that improvements in these metrics are correlated. OBJECTIVE: Investigate the relationship between HRQoL and measures of PD severity and treatment efficacy, including motor and non-motor symptoms. METHODS: This was a planned investigation of an international, prospective, single-arm, post-marketing observational study of the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD. Pearson correlation coefficients (PCC) were calculated for baseline and change from baseline at 12 months between HRQoL and motor and NEUROLOGIE 47